Hangzhou Winonco Medical Technology Co., Ltd. is a national high-tech enterprise focused on the field of minimally invasive tumor ablation. Driven by clinical needs, the company is dedicated to advancing innovative medical technology R&D. At its core is a proprietary high-voltage pulsed electric field irreversible electroporation (IRE) technology, integrated into a multi-physics, multi-modal platform to develop internationally leading minimally invasive tumor ablation solutions.

The company was founded by overseas returnees from Europe and the United States, along with internationally recognized scientists. It boasts a high-level interdisciplinary R&D team spanning electrical engineering, biology, medicine, and clinical disciplines – a true integration of engineering and medicine. With its world-leading pulsed field ablation technology platform and clinically-oriented system solutions, the company has been awarded key projects from the National Natural Science Foundation of China (NSFC), as well as multiple national key R&D programs and NSFC grants. Winner Anke holds full independent intellectual property rights in IRE technology, with over 200 domestic and international patent applications filed (including 18 PCT patents). The company is committed to driving continuous technological innovation and clinical translation, delivering safer, more minimally invasive, and more accessible Chinese solutions for patients worldwide.